Completed NA INTERVENTIONAL 2-arm NCT05447039

Value of Montelukast as a Potential Treatment of Post COVID-19 Persistent Cough

Value of Montelukast as a Potential Treatment of Post COVID-19 Persistent Cough: A Randomized Controlled Pilot Study

Sponsor: Assiut University

Interventions Montelukast Sodium Tablets

Updated 4 times since 2022 Last updated: Jul 5, 2022 Started: Sep 1, 2020 Primary completion: Nov 30, 2020 Completion: Mar 30, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05447039, this NA trial focuses on Post COVID-19 and remains completed. Sponsored by Assiut University, it has been updated 4 times since 2020, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

4 versions recorded

Sep 2025 — Present [monthly]

Completed NA
Sep 2024 — Sep 2025 [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Sep 2022 — Jul 2024 [monthly]

Completed NA

First recorded

Sep 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Assiut University

Data source: Assiut University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Asyut, Egypt